{
    "id": "5035e520-d797-4663-8642-6020e5cee8e7",
    "indications": "RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.",
    "contraindications": "Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with RYSTIGGO. ( 2.1 ) For subcutaneous infusion only. ( 2.2 ) The recommended dosage is administered as a subcutaneous infusion once weekly for 6 weeks. ( 2.2 ) Body Weight of Patient Dose Volume to be Infused Less than 50 kg 420 mg 3 mL 50 kg to less than 100 kg 560 mg 4 mL 100 kg and above 840 mg 6 mL Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established. ( 2.2 )",
    "adverseReactions": "None.",
    "ingredients": [
        {
            "name": "ROZANOLIXIZUMAB",
            "code": "P7186074QC"
        }
    ],
    "organization": "UCB, Inc.",
    "name": "RYSTIGGO",
    "effectiveTime": "20250506"
}